Nanotechnology in oncology: Characterization and in vitro release kinetics of cisplatin-loaded albumin nanoparticles: Implications in anticancer drug delivery

Indian Journal of Pharmacology

Volumn 43, Issue 4, 2011, Pages 409-413

  Das, Saikat ^a   Jagan, Lavanya ^a   Isiah, Rajesh ^a   Rajesh, B ^a   Backianathan, Selvamani ^a   Subhashini, J ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Albumin nanoparticle; carcinoma cervix; cisplatin; coacervation; nanobiotechnology

Indexed keywords

BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMIN NANOPARTICLE; CISPLATIN; GLUTARALDEHYDE; NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; FEASIBILITY STUDY; IN VITRO STUDY; LIGHT SCATTERING; MICROENCAPSULATION; NANOTECHNOLOGY; PARTICLE SIZE; SUSTAINED RELEASE FORMULATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY;

EID: 80053274456     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.83111     Document Type: Article

References (25)

1. Tao Y, Daly-Schveitzer N, Lusinchi A, Bourhis J. Advances in radiotherapy of head and neck cancers. Curr Opin Oncol 2010;22:194-9.
2. Pignon J, le Maître A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
3. Joly-Lobbedez F. Evidence based of chemoradiotherapy in cervix carcinoma. Cancer Radiother 2009;13:503-6.
4. Ehara K, Tsutsumi K, Kinoshita Y, Ueno M, Mine S, Udagawa H. A case of advanced esophageal cancer with liver metastases: Efficacy of combination therapy of docetaxel/cisplatin/5-FU. Gan To Kagaku Ryoho 2008;35:1375-8.
5. Sakurai H, Okamoto M, Hasegawa M, Satoh T, Oikawa M, Kamiya T, et al. Direct visualization and quantification of the anticancer agent, cis-diamminedichloroplatinum (II), in human lung cancer cells using in-air microparticle-induced X-ray emission analysis. Cancer Sci 2008;99:901-4. (Pubitemid 351997591)
6. Benjamin RS, Patel SR. Pediatric and adult osteosarcoma: Comparisons and contrasts in presentation and therapy. Cancer Treat Res 2010;152:355-63.
7. Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: Clinical and experimental studies. Tohoku J Exp Med 2009;219:177-86.
8. Serkies K, Jassem J. Concurrent weekly cisplatin and radiotherapy in routine management of cervical cancer: A report on patient compliance and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60:814-21. (Pubitemid 39311761)
9. Arayne MS, Sultana N. Review: Nanoparticles in drug delivery for the treatment of cancer. Pak J Pharm Sci 2006;19:258-68.
10. Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003;257:169-80. (Pubitemid 36507043)
11. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nanoand microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998;46:255-63. (Pubitemid 29057671)
12. Lin W, Garnett MC, Davis SS, Schacht E, Ferruti P, Illum L. Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. J Control Release 2001;71:117-26. (Pubitemid 32195446)
13. Merodio M, Arnedo A, Renedo MJ, Irache JM. Ganciclovir-loaded albumin Nanoparticles: Characterization and in vitro release properties. Eur J Pharm Sci 2001;12:251-9.
14. Merodio M, Irache JM, Valamanesh F, Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 2002;23:1587-94. (Pubitemid 34158581)
15. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002;16:53-61. (Pubitemid 34756782)
16. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nanoand microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm 1998;46:255-63. (Pubitemid 29057671)
17. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbatebased docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909.
18. Tseng CL, Su WY, Yen KC, Yang KC, Lin FH. The use of biotinylated-EGF- modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials 2009;30:3476-85.
19. Bourikas T. Clinical overview on Lipoplatin: A successful liposomal formulation of cisplatin. Expert Opin Investing Drugs 2009;18:1197-218.
20. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K. In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-peg nanoparticles. Eur J Pharm Biopharm 2009;71:190-5.
21. Tian J, Pang X, Yu K, Liu L, Zhou J. Preparation, characterization and in vivo distribution of solid lipid nanoparticles loaded with cisplatin. Pharmazie 2008;63:593-7.
22. Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, et al. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts. Anticancer Drugs 2008;19:721-7.
23. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008;127:41-9.
24. Moreno D, de Ilarduya CT, Bandrés E, Buñuales M, Azcona M, García-Foncillas J, et al. Characterization of cisplatin cytotoxicity delivered from PLGA-systems. Eur J Pharm Biopharm 2008;68:503-12. (Pubitemid 351318205)
25. Li X, Li R, Qian X, Ding Y, Tu Y, Guo R, et al. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm 2008;70:726-34.